These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9838964)

  • 1. The withdrawal of mibefradil (Posicor).
    Griffin JP
    Adverse Drug React Toxicol Rev; 1998; 17(2-3):59-60. PubMed ID: 9838964
    [No Abstract]   [Full Text] [Related]  

  • 2. Withdrawal of Posicor from market.
    SoRelle R
    Circulation; 1998 Sep; 98(9):831-2. PubMed ID: 9738634
    [No Abstract]   [Full Text] [Related]  

  • 3. What lessons can be learnt from withdrawal of mibefradil from the market?
    Po AL; Zhang WY
    Lancet; 1998 Jun; 351(9119):1829-30. PubMed ID: 9652662
    [No Abstract]   [Full Text] [Related]  

  • 4. Mibefradil (posicor).
    Giles TD
    Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
    [No Abstract]   [Full Text] [Related]  

  • 5. Mibefradil withdrawn from the market.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998; 32(7-8):841. PubMed ID: 9681103
    [No Abstract]   [Full Text] [Related]  

  • 6. Mibefradil--a new calcium-channel blocker.
    Med Lett Drugs Ther; 1997 Nov; 39(1013):103-5. PubMed ID: 9391500
    [No Abstract]   [Full Text] [Related]  

  • 7. Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy.
    Rogers R; Prpic R
    Med J Aust; 1998 Oct; 169(8):425-7. PubMed ID: 9830391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Induction of bradycardia by mibefradil in antihypertensive combination therapy].
    Wagner J; Ritz E
    Dtsch Med Wochenschr; 1998 Apr; 123(17):547. PubMed ID: 9601479
    [No Abstract]   [Full Text] [Related]  

  • 9. Mibefradil (Posicor) induced sinus arrest.
    Sanders P; Walker J; Craig RJ; Hii JT; Steele PM
    Aust N Z J Med; 1998 Dec; 28(6):836-7. PubMed ID: 9972419
    [No Abstract]   [Full Text] [Related]  

  • 10. Comment: mibefradil, a new class of calcium-channel antagonists.
    Otterman S
    Ann Pharmacother; 1998 Dec; 32(12):1372. PubMed ID: 9876826
    [No Abstract]   [Full Text] [Related]  

  • 11. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
    Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
    Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
    [No Abstract]   [Full Text] [Related]  

  • 12. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin.
    Wombolt DG; Jackson A; Punn R; Smith S; McCune TR; Williams PB
    J Clin Pharmacol; 1999 Mar; 39(3):310-2. PubMed ID: 10073331
    [No Abstract]   [Full Text] [Related]  

  • 13. Mibefradil and an effective formulary system.
    Vermeulen LC; Dunham DB
    Am J Health Syst Pharm; 1998 Sep; 55(18):1934-5. PubMed ID: 9784776
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current therapy of coronary heart disease. Conservative measures].
    Stephan S
    Internist (Berl); 1998 Sep; 39(9):1001-2. PubMed ID: 9788131
    [No Abstract]   [Full Text] [Related]  

  • 15. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1998 Feb; 279(5):346. PubMed ID: 9459455
    [No Abstract]   [Full Text] [Related]  

  • 16. The short life and rapid death of a novel antihypertensive and antianginal agent.
    Krum H; McNeil JJ
    Med J Aust; 1998 Oct; 169(8):408-9. PubMed ID: 9830386
    [No Abstract]   [Full Text] [Related]  

  • 17. Roche cites drug interactions in mibefradil withdrawal.
    Am J Health Syst Pharm; 1998 Jul; 55(14):1445. PubMed ID: 9676286
    [No Abstract]   [Full Text] [Related]  

  • 18. Good news for experimental concept but bad news for clinically effective therapy.
    Reimer KA; Califf RM
    Circulation; 1999 Jan; 99(2):198-200. PubMed ID: 9892582
    [No Abstract]   [Full Text] [Related]  

  • 19. Serious interaction between mibefradil and tacrolimus.
    Krähenbühl S; Menafoglio A; Giostra E; Gallino A
    Transplantation; 1998 Oct; 66(8):1113-5. PubMed ID: 9808502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in new cardiovascular treatment. Background discussion and interview in the Basel Roche Research Center].
    Keil U
    Fortschr Med; 1996 Feb; 114(4):39-40. PubMed ID: 8852686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.